Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Chao-Ting Wu
Harvard Medical School, Department: Genetics
Should you be removed from our database? Contact us at [email protected]. Read more below.
Twist Bioscience
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This research project includes in situ genome profiling through Oligopaints, FISSEQ, ExSeq and related methods. Dr. Wu's spouse holds private equity in Twist Biosciences. Twist Bioscience’s products include Oligo pools, high diversity collections of oligonucleotides, which can be utilized in many applications, including generation of CRISPR guide RNA (sgRNA) libraries and high-throughput reporter assays.
Center for Genomically Engineered Organs
The Center for Genomically Engineered Organs will develop methods for making tissues in laboratories that closely match normal or diseased tissues in humans and animals. Such model tissues will accelerate biomedical research by providing easy ways to conduct preliminary tests of theories of normal tissue function, or that explore the effects of diseases and treatments, before moving to potentially invasive experiments or costly clinical trials. The Center will use cutting edge methods that allow vast number of individual molecules of DNA, RNA, and protein to be visualized in the individual cells of tissues, enable stem cells to be genetically edited and reprogrammed into other cell types, and that permit cells of different types to be assembled into complex vascularized tissues.
Filed on August 17, 2018.
Tell us what you know about Chao-Ting Wu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Chao-Ting Wu”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Chao-Ting Wu | Harvard Medical School | Conflict of Interest | ReadCoor, Inc. | Value cannot be readily determined |
| Chao-Ting Wu | Harvard Medical School | Conflict of Interest | Twist Bioscience | Value cannot be readily determined |
| Chao-Ting Wu | Harvard Medical School | Conflict of Interest | GC Therapeutics | Value cannot be readily determined |
| Chao-Ting Wu | Harvard Medical School | Conflict of Interest | ReadCoor | Value cannot be readily determined |
| Chao-Ting Wu | Harvard Medical School | Conflict of Interest | GC Therapeutics | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.